How Much Do You Know About Acs?
Test your knowledge about the screening, treatment, management and prevention of ACS events.
- 1.Which of the following is the initial treatment regimen for patients with ACS?
- A.
Aspirin, clopidogrel, unfractionated heparin or low–molecular-weight heparin, IV platelet glycoprotein IIb/IIIa complex blockers and a beta-blocker
- B.
Morphine for pain, oxygen, sublingual or IV nitroglycerin, soluble aspirin between 162 mg and 325 mg and clopidogrel between 300 mg and 600 mg loading dose
- C.
None of the above
- 2.What did the recent SOLID-TIMI 52 trial find regarding treatment with darapladib?
- A.
Darapladib failed to reduce the risk for coronary events when compared with placebo
- B.
Darapladib reduced the risk for coronary events when compared with placebo
- C.
Darapladib led to a 67% death rate
- 3.In 2012, which medication did the FDA reject as a treatment for patients with ACS?
- A.
Rivaroxaban
- B.
Clopidogrel
- C.
Prasugrel
- 4.Other than obesity, which of the following health conditions is associated with an increased risk for ACS?
- A.
Rhinosinusitis
- B.
Allergies
- C.
Insomnia
- 5.Which of the following is the most common symptom of ACS?
- A.
Chest pain
- B.
Cough
- C.
Lethargy
- 6.Chest pain that is unpredictable and gets worse even with rest is a symptom of which of the following?
- A.
Diabetes
- B.
Salmonella
- C.
Unstable angina
- 7.Which of the following is a test used to diagnose ACS?
- A.
ECG
- B.
Mammogram
- C.
Glucose test
- 8.Although delays are known to occur throughout emergency ACS care, which patient group is most affected according to results from the IMMEDIATE trial?
- A.
Men
- B.
Older women
- C.
Women aged between 25 and 45 years
- 9.Which trial found that the presence of high-risk plaque detected by coronary CTA in the emergency department was associated with an increased risk for ACS in those with acute chest pain?
- A.
OPTIMA
- B.
TRILOGY ACS
- C.
ROMICAT - II
- 10.In 2011, which of the following medications did the FDA approve for the reduction of MI and CV death in patients with ACS?
- A.
Ticagrelor
- B.
Iron supplementation
- C.
Ibrutinib
Back to top